Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis

References

• Murray TJ. Diagnosis and treatment of multiple sclerosis. Br. Med. J.332, 525–527 (2006).
   PubMed Web of Science ®Google Scholar
• Swanton JK, Rovira A, Tintore M et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol.6(8), 677–686 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis – a multifaceted adversary. Nat. Rev. Drug Discov.7, 909–925 (2008).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol.8, 545–559 (2009).
   PubMed Web of Science ®Google Scholar
• Rio J, Nos C, Tintore M et al. Defining the response to interferon-β in relapsing–remitting multiple sclerosis patients. Ann. Neurol.59, 344–352 (2006).
   PubMed Web of Science ®Google Scholar
• Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin. Neuropharmacol.32, 121–132 (2009).
   PubMed Web of Science ®Google Scholar
• Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int. Rev. Neurobiol.79, 43–72 (2007).
   PubMed Web of Science ®Google Scholar
• De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu. Rev. Med.58, 417–432 (2007).
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol. Res.28, 236–244 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int. J. Clin. Pract.61, 1922–1930 (2007).
   PubMed Web of Science ®Google Scholar
• Portaccio E, Amato MP. Improving compliance with interferon-β therapy in patients with multiple sclerosis. CNS Drugs23, 453–462 (2009).
   PubMed Web of Science ®Google Scholar
• Rizvi SA, Kim E, Moodie J. Glatiramer in the treatment of multiple sclerosis. Int. J. Nanomedicine1, 283–289 (2006).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Toyka KV, Rieckmann P, Gold R, Hartung HP, Hohlfeld R. Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J. Neurol255, 1449–1463 (2008).
   PubMed Web of Science ®Google Scholar
• Ball NJ, Cowan BJ, Hashimoto SA. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases. J. Cutan. Pathol.35, 407–410 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B et al.; BEYOND Study Group. 250 microg or 500 microg interferon β-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol.8(10), 889–897 (2009).
   PubMed Web of Science ®Google Scholar
• Kappos L, Gold R, Miller DH et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet372, 1463–1472 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med.355, 1124–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 402–415 (2010).
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med.362(5), 387–401 (2010).
   PubMed Web of Science ®Google Scholar
• Comi G, Pulizzi A, Rovaris M et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled Phase IIb study. Lancet371, 2085–2092 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connor PW, Li D, Freedman MS et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology66, 894–900 (2006).
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW et al. Alemtuzumab vs. interferon β-1a in early multiple sclerosis. N. Engl. J. Med.359, 1786–1801 (2008).
   PubMed Web of Science ®Google Scholar
• Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr. Med. Res. Opin.23, 2667–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Sipe JC. Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother.5, 721–727 (2005).
   PubMedGoogle Scholar
• King KM, Damaraju VL, Vickers MF et al. A comparison of the transportability, and its role in cytotoxicity, of clofarabine, cladribine, and fludarabine by recombinant human nucleoside transporters produced in three model expression systems. Mol. Pharmacol.69, 346–353 (2006).
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia18, 385–393 (2004).
   PubMed Web of Science ®Google Scholar
• Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E, Casado FJ. SLC28 genes and concentrative nucleoside transporter (CNT) proteins. Xenobiotica38, 972–994 (2008).
   PubMed Web of Science ®Google Scholar
• Preusch P. equilibrative and concentrative transport mechanisms. In: Principles of Clinical Pharmacology. Atkinson A, Abernethy D, Daniels C, Dedrick R, Markey S (Eds). Academic Press, MA, USA, 197–227 (2007)
   Google Scholar
• Carson DA, Wasson DB, Kaye J et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. USA77, 6865–6869 (1980).
   PubMed Web of Science ®Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5’-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blood81, 597–601 (1993).
   PubMed Web of Science ®Google Scholar
• Carson DA, Carrera CJ, Wasson DB, Iizasa T. Deoxyadenosine-resistant human T lymphoblasts with elevated 5’-nucleotidase activity. Biochim. Biophys. Acta1091, 22–28 (1991).
   PubMed Web of Science ®Google Scholar
• Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann. Intern. Med.120, 784–791 (1994).
   PubMed Web of Science ®Google Scholar
• Spasokoukotskaja T, Arner ES, Brosjo O et al. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer31A, 202–208 (1995).
   PubMed Web of Science ®Google Scholar
• Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res.49, 6923–6928 (1989).
   PubMed Web of Science ®Google Scholar
• Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin. Hematol.31, 40–45 (1994).
   PubMed Web of Science ®Google Scholar
• Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology54, 1145–1155 (2000).
   PubMed Web of Science ®Google Scholar
• Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians111, 35–44 (1999).
   PubMedGoogle Scholar
• Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet344, 9–13 (1994).
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl Acad. Sci. USA93, 1716–1720 (1996).
   PubMed Web of Science ®Google Scholar
• Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin. Hematol.33, 45–52 (1996).
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Comi G, Cook S et al. Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96 week, Phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12 2009. Mult. Scler.15, S248–S249 (2009).
   Google Scholar
• Soelberg-Sorensen P, Comi G, Cook S et al. Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis (RRMS) in the 96 week, Phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12, 2009. Mult. Scler.15, S137 (2009).
   Google Scholar
• Salvat C, Curchod ML, Guedj E et al. Cellular expression profiling of genes involved in the cladribine metabolic pathway: insights into mechanism of action in multiple sclerosis. Procedings and Abstracts of the Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dusseldorf, Germany, 9–12 September, 2009 (Poster presentation P280).
   Google Scholar
• Liliemark J. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet.32, 120–131 (1997).
   PubMed Web of Science ®Google Scholar
• Albertioni F, Juliusson G, Liliemark J. On the bioavailability of 2-chloro-2’-deoxyadenosine (CdA). The influence of food and omeprazole. Eur. J. Clin. Pharmacol.44, 579–582 (1993).
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Comi G, Cook S et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med.362(5), 416–426 (2010).
   PubMed Web of Science ®Google Scholar
• Comi C, Cook S, Giovannoni G et al. Magnetic resonance imaging (MRI) outcomes in patients with relapsing–remitting multiple sclerosis (RRMS) treated with cladribine tablets: results from the CLARITY study, a 96-week, Phase III, double-blind, placebo-controlled trial. Program and Abstracts of the European Neurological Society (ENS). Milan, Italy, 20–24 June, 2009 (Oral presentation O132).
   Google Scholar
• Giovannoni G, Comi G, Cook S et al. Results from the CLARITY study: a Phase III, randomized, double-blind study to evaluated the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis (RRMS), Meeting Abstract, Annual Meeting of the American Academy of Neurology (AAN), Seattle, USA, 25 April–2 May 2009. Neurology73, 330 (2009).
   Google Scholar
• Giovannoni G, Comi G, Cook S et al. Clinical outcomes with cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis. Meeting Abstract, Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Dusseldorf, Germany, September 9–12 2009. Mult. Scler.15, S136–S137 (2009).
   Web of Science ®Google Scholar
• Cook S, Vermersch P, Comi G et al. Safety of cladribine tablets in relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, Phase III, double-blind, placebo-controlled trial. Meeting Abstract. European Neurological Society (ENS), Milan, Italy, June 20–24 2009. J. Neurol.256, S128 (2009).
   Google Scholar
• Cook S, Vermersch P, Comi G et al. Safety of cladribine tablets in relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96-week, Phase III, double-blind, placebo-controlled trial. Program and Abstracts of the European Neurological Society (ENS) Meeting. Milan, Italy, June 20–24, 2009 (Poster presentation P360).
   Google Scholar
• Cook S, Vermersch P, Comi G et al. Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis (RRMS) during the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Dusseldorf, Germany, 9–12 September, 2009 (Oral presentation 88).
   Google Scholar
• Cook S, Vermersch P, Comi G et al. Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis (RRMS) during the 96-week, Phase III, double-blind, placebo-controlled CLARITY study. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12,S 2009. Mult. Scler.15, S20 (2009).
   Google Scholar
• Viglietta V, Greenberg S, Mikol D et al. Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12 2009. Mult. Scler.15, S126–S127 (2009).
   Google Scholar
• Miret M, Perez-Gutthann S, Gutierrez L, Viglietta V, Musch B, Greenberg S. Evaluation of the long-term safety of cladribine tablets: design of a prospective observational 8-year safety registry. Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12 2009). Mult. Scler.15, S239 (2009).
   Google Scholar
• Giovannoni G, Comi G, Rammohan K et al. Disease-free status achieved with cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis (RRMS). Meeting Abstract. Annual Congress of European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Dusseldorf, Germany, September 9–12, 2009. Mult. Scler.15, S137 (2009).
   Google Scholar
• Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ. Marrow suppression produced by repeated doses of cladribine. Acta Haematol.91, 10–15 (1994).
   PubMed Web of Science ®Google Scholar